Suggestions
Chandra P. Leo
We Invest in the Future of Medicine
Chandra P. Leo is an accomplished venture capital investor with a background in medicine and business administration, focusing on supporting innovative healthcare companies in the United States and Europe. With a unique blend of MD and MBA degrees, Chandra has played a crucial role in investments in over 25 private biotech, medical device, and diagnostics companies, yielding notable results like eleven NASDAQ IPOs, six M&A deals, and six FDA-approved products.
Chandra's investment portfolio showcases a commitment to cutting-edge healthcare solutions, with current interests spanning companies such as Dren Bio, eGenesis, Fore Biotherapeutics, Karius, Monte Rosa Therapeutics, and River Renal. These ventures cover diverse areas like malignant cell depletion, xenotransplantation, precision oncology, liquid biopsy, targeted protein degradation, and novel nephrology drugs.
His expertise extends across venture capital, corporate venture capital, growth capital, private equity, pharma, biotech, women's health, gynecology, medtech, diagnostics, and life sciences. Drawing from a rich educational background that includes an MBA from INSEAD, an MD from Freie Universität Berlin, and additional studies in medicines development and non-executive directorship, Chandra combines medical insights with business acumen in his investment strategies.
Prior to his current roles, Chandra held positions of significance at renowned organizations such as HBM Partners and Wellington Partners. His early career saw him contributing as a Physician at University Hospital Leipzig and as a Postdoctoral Scientist at Stanford University, nurturing a well-rounded perspective on healthcare innovation.
Chandra P. Leo's professional journey mirrors a dedication to fostering advancements in healthcare through strategic investments and board engagements, making him a prominent figure in the field of venture capital and healthcare innovation.
Highlights
💊📈 Great to see the successful biotech IPO of our portfolio company Mineralys Therapeutics, Inc. Congratulations to the entire team, led by CEO Jon Congleton, CMO David Rodman and CFO/CBO Adam Levy, as well as to our HBM Partners AG colleague and Mineralys board member Dr. Alexander Asam, and our co-investors including Catalys Pacific, Andera, RA Capital and Samsara. Mineralys ($MLYS) will use the $192 million from its upsized IPO offering to fund late-stage clinical trials for its oral drug lorundrostat. This selective aldosterone inhibitor is in development for diseases driven by abnormally elevated aldosterone, including uncontrolled arterial hypertension. https://lnkd.in/ecuH6pte #ipo #biotech #hypertension #nasdaq #pharma
